Page last updated: 2024-08-21

dronabinol and Sclerosis, Systemic

dronabinol has been researched along with Sclerosis, Systemic in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Bloom, BJ; Chung, L; Constantine, S; de Vries-Bouwstra, J; Denton, CP; Dgetluck, N; Dinh, Q; Distler, O; Finzel, S; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Jankowski, T; Jun, JB; Kafaja, S; Khanna, D; Kuwana, M; Lee, EB; Leszcyzński, P; Levy, Y; Litinsky, I; Matucci-Cerinic, M; Mayes, M; Sandorfi, N; Simms, RW; Spiera, R; Steen, V; Stevens, W; White, B1
Chung, L; Constantine, S; Dgetluck, N; Domsic, R; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Lafyatis, R; Lee, E; Martyanov, V; Mayes, M; Simms, R; Spiera, R; White, B; Whitfield, ML; Wood, T1
Akhmetshina, A; Baldi, C; Balistreri, E; Capecchi, PL; Distler, JH; Galeazzi, M; Gianchecchi, E; Gonzalez, EG; Lazzerini, PE; Lorenzini, S; Lucattelli, M; Montilli, C; Palumbo, K; Pasini, FL; Selvi, E1

Trials

2 trial(s) available for dronabinol and Sclerosis, Systemic

ArticleYear
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:9

    Topics: Cannabinoid Receptor Agonists; Dronabinol; Humans; Scleroderma, Diffuse; Scleroderma, Systemic; Severity of Illness Index; Skin; Treatment Outcome

2023
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
    Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:8

    Topics: Adolescent; Adult; Aged; Cannabinoid Receptor Agonists; Double-Blind Method; Dronabinol; Drugs, Investigational; Female; Humans; Male; Middle Aged; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Severity of Illness Index; Skin; Synthetic Drugs; Treatment Outcome; Young Adult

2020

Other Studies

1 other study(ies) available for dronabinol and Sclerosis, Systemic

ArticleYear
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis.
    Annals of the rheumatic diseases, 2012, Volume: 71, Issue:9

    Topics: Adult; Aged; Animals; Cannabinoids; Collagen; Disease Models, Animal; Dronabinol; Female; Fibroblasts; Fibrosis; Humans; Male; Mice; Middle Aged; Scleroderma, Systemic

2012